| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13G · 1 security · passive | ||||||
|
MapLight Therapeutics, Inc.
13G
MPLT · 56565P103
|
5.5% |
8/20/2026
Event 8/13/2026
|
||||
| Nan Fung Group Holdings Limited | 5.5% | |||||
| NF Investment Holdings Limited | 5.5% | |||||
| Nan Fung Life Sciences Holdings Limited | 2.4% | |||||
| NFLS Platform Holdings Limited | 1.3% | |||||
| Pivotal Life Sciences Holdings Limited | 1.2% | |||||
| Pivotal Partners Ltd | 1.2% | |||||
| Pivotal bioVenture Partners Fund II G.P. Ltd | 1.2% | |||||
| Pivotal bioVenture Partners Fund II, L.P. | 1.2% | |||||
| NFLS Beta Limited | 1.3% | |||||
| Permwell Management Limited | 3.1% | |||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.